Fulcrum Therapeutics Q3 net loss $21.7M, cash $257.2M; losmapimod halted, PIONEER trial ongoing

Fulcrum Therapeutics, Inc.

2024-Q3 EPS reported $0.11 revenue$80,000,000

Net loss $21.7M in Q3 2024 vs $24.0M loss in Q3 2023; R&D expenses down to $14.6M from $18.2M.
Cash $257.2M as of Sept 30, 2024, up from $236.2M at Dec 31, 2023, due to $80M Sanofi upfront.
Phase 1b PIONEER trial for pociredir (SCD) advancing; Cohorts 3 (12mg) and 4 (20mg) planned; data expected 2025.
Losmapimod development suspended after Phase 3 REACH failure; company refocuses on pociredir and aplastic anemias.
Cash runway into at least 2027; FY2025 cash burn guided at $55-65M; expects ~$240M cash at end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.